Drug Profile
Research programme: nerve injury therapeutics - Galapagos/NeuroTargets
Latest Information Update: 13 Apr 2007
Price :
$50
*
At a glance
- Originator Galapagos NV; NeuroTargets
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain; Spinal cord injuries
Most Recent Events
- 13 Apr 2007 No development reported - Preclinical for Pain in United Kingdom (unspecified route)
- 13 Apr 2007 No development reported - Preclinical for Spinal cord injuries in United Kingdom (unspecified route)
- 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV